Roland Goette - 11 Aug 2026 Form 4 Insider Report for BECTON DICKINSON & CO (BDX)

Reporting relationship: EVP and President, EMEA
Issuer ticker: BDX
Reported as of: 11 Aug 2026
Net transaction value: -$440,888
SEC form: 4
Accepted by SEC: 12 Aug 2026, 17:27:20 UTC
Prior SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: Donna Kalazdy, by power of attorney from Roland Goette

Key filing fact

Roland Goette filed Form 4 for BECTON DICKINSON & CO (BDX) on 12 Aug 2026.

Key facts

This page summarizes Roland Goette's Form 4 filing for BECTON DICKINSON & CO (BDX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 17:27.

Change

Previous filing in this sequence was filed on 01 Dec 2025.
Current net transaction value: -$440,888.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001708067 Primary reporting owner

Goette Roland

Relationship: EVP and President, EMEA
Address: C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES
Signature: Donna Kalazdy, by power of attorney from Roland Goette
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BDX transaction

Common Stock

Sale

Transaction value: $440,888
Shares: -2,438
Change %: -14%
Price: $180.84
Shares after: 14,856
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1, F2

BDX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,779
Date: 11 Aug 2026
Ownership: GSIP Trust
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Securities sold were common stock acquired through the Becton, Dickinson and Company Global Share Investment Program (the "GSIP").

Footnote F2

Holdings reflect the addition of dividends the reporting person received as part of the equity adjustment made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

Footnote F3

Represents shares of common stock held under the Becton, Dickinson and Company Global Share Investment Program (the "GSIP"). The information presented for the GSIP is as of August 3, 2026.